A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I - Eriksson, BI; Arfwidsson, A-C; Frison, L; Eriksson, UG; Bylock, A; Kälebo, P (Thromb Haemost, 2002)
et al.